Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia

on behalf of the DAPPER Study Team

Research output: Contribution to journalArticle

Abstract

Introduction: There are no validated, practical, and quantitative measures of disease severity in Lambert-Eaton myasthenia (LEM). Methods: Data from the Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (DAPPER) trial were analyzed to assess triple timed up-and-go (3TUG) reproducibility and relationships between 3TUG times and other measures of LEM severity. Results: The coverage probability technique showed ≥0.90 probability for an acceptable 3TUG difference of ≤0.2, indicating that it is reproducible in LEM patients. The correlation between 3TUG times and lower extremity function scores was significant in subjects who continued and in those who were withdrawn from 3,4-diaminopyridine free base. Worsening patient-reported Weakness Self-Assessment Scale and Investigator Assessment of Treatment Effect scores corresponded with prolongation of 3TUG times. Discussion: The 3TUG is reproducible, demonstrates construct validity for assessment of lower extremity function in LEM patients, and correlates with changes in patient and physician assessments. These findings, along with prior reliability studies, indicate 3TUG is a valid measure of disease severity in LEM.

Original languageEnglish (US)
JournalMuscle and Nerve
DOIs
StatePublished - Jan 1 2019

Fingerprint

Lower Extremity
Lambert-Eaton Myasthenic Syndrome
Research Personnel
Physicians
3,4-diaminopyridine
Therapeutics
Self-Assessment

Keywords

  • Lambert-Eaton myasthenia
  • Lambert-Eaton myasthenic syndrome
  • Lambert-Eaton syndrome
  • outcome measures
  • timed up-and-go test
  • validation

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia. / on behalf of the DAPPER Study Team.

In: Muscle and Nerve, 01.01.2019.

Research output: Contribution to journalArticle

@article{7f49bf2332284c46a631f389e668734c,
title = "Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia",
abstract = "Introduction: There are no validated, practical, and quantitative measures of disease severity in Lambert-Eaton myasthenia (LEM). Methods: Data from the Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (DAPPER) trial were analyzed to assess triple timed up-and-go (3TUG) reproducibility and relationships between 3TUG times and other measures of LEM severity. Results: The coverage probability technique showed ≥0.90 probability for an acceptable 3TUG difference of ≤0.2, indicating that it is reproducible in LEM patients. The correlation between 3TUG times and lower extremity function scores was significant in subjects who continued and in those who were withdrawn from 3,4-diaminopyridine free base. Worsening patient-reported Weakness Self-Assessment Scale and Investigator Assessment of Treatment Effect scores corresponded with prolongation of 3TUG times. Discussion: The 3TUG is reproducible, demonstrates construct validity for assessment of lower extremity function in LEM patients, and correlates with changes in patient and physician assessments. These findings, along with prior reliability studies, indicate 3TUG is a valid measure of disease severity in LEM.",
keywords = "Lambert-Eaton myasthenia, Lambert-Eaton myasthenic syndrome, Lambert-Eaton syndrome, outcome measures, timed up-and-go test, validation",
author = "{on behalf of the DAPPER Study Team} and Raja, {Shruti M.} and Sanders, {Donald B.} and Juel, {Vern C.} and Yadollah Harati and Smith, {A. Gordon} and Robert Pascuzzi and Richman, {David P.} and Angie Wu and Aleš, {Kathy L.} and Jacobus, {Laura R.} and Jacobus, {David P.} and Guptill, {Jeffrey T.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/mus.26625",
language = "English (US)",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia

AU - on behalf of the DAPPER Study Team

AU - Raja, Shruti M.

AU - Sanders, Donald B.

AU - Juel, Vern C.

AU - Harati, Yadollah

AU - Smith, A. Gordon

AU - Pascuzzi, Robert

AU - Richman, David P.

AU - Wu, Angie

AU - Aleš, Kathy L.

AU - Jacobus, Laura R.

AU - Jacobus, David P.

AU - Guptill, Jeffrey T.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: There are no validated, practical, and quantitative measures of disease severity in Lambert-Eaton myasthenia (LEM). Methods: Data from the Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (DAPPER) trial were analyzed to assess triple timed up-and-go (3TUG) reproducibility and relationships between 3TUG times and other measures of LEM severity. Results: The coverage probability technique showed ≥0.90 probability for an acceptable 3TUG difference of ≤0.2, indicating that it is reproducible in LEM patients. The correlation between 3TUG times and lower extremity function scores was significant in subjects who continued and in those who were withdrawn from 3,4-diaminopyridine free base. Worsening patient-reported Weakness Self-Assessment Scale and Investigator Assessment of Treatment Effect scores corresponded with prolongation of 3TUG times. Discussion: The 3TUG is reproducible, demonstrates construct validity for assessment of lower extremity function in LEM patients, and correlates with changes in patient and physician assessments. These findings, along with prior reliability studies, indicate 3TUG is a valid measure of disease severity in LEM.

AB - Introduction: There are no validated, practical, and quantitative measures of disease severity in Lambert-Eaton myasthenia (LEM). Methods: Data from the Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (DAPPER) trial were analyzed to assess triple timed up-and-go (3TUG) reproducibility and relationships between 3TUG times and other measures of LEM severity. Results: The coverage probability technique showed ≥0.90 probability for an acceptable 3TUG difference of ≤0.2, indicating that it is reproducible in LEM patients. The correlation between 3TUG times and lower extremity function scores was significant in subjects who continued and in those who were withdrawn from 3,4-diaminopyridine free base. Worsening patient-reported Weakness Self-Assessment Scale and Investigator Assessment of Treatment Effect scores corresponded with prolongation of 3TUG times. Discussion: The 3TUG is reproducible, demonstrates construct validity for assessment of lower extremity function in LEM patients, and correlates with changes in patient and physician assessments. These findings, along with prior reliability studies, indicate 3TUG is a valid measure of disease severity in LEM.

KW - Lambert-Eaton myasthenia

KW - Lambert-Eaton myasthenic syndrome

KW - Lambert-Eaton syndrome

KW - outcome measures

KW - timed up-and-go test

KW - validation

UR - http://www.scopus.com/inward/record.url?scp=85069827891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069827891&partnerID=8YFLogxK

U2 - 10.1002/mus.26625

DO - 10.1002/mus.26625

M3 - Article

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

ER -